info@marketlookconsulting.com +1 347 441 0939

Global Aminoglycosides Market Report, Industry Analysis and Forecast to 2029

Request for Sample
  1. Home
  2. Healthcare
  3. Aminoglycosides market

Aminoglycosides Market Report- Global Strategic Analysis, Size, Share, Trend, and Forecast (2022-2029)

Social Share Button
Healthcare

Aminoglycosides Market Outlook (2025–2035)

The aminoglycosides market, encompassing antibiotics like gentamicin and tobramycin used primarily for treating bacterial infections, is expected to see moderate growth due to rising antimicrobial resistance and demand in respiratory and skin infection treatments. The provided CAGR of 4.15% and projected value of USD 3 billion in 2035 align with forecasts emphasizing innovations in formulations to address toxicity concerns.

Market Size and Projections

The global aminoglycosides market is projected to grow from USD 2.00 billion in 2025 to USD 3.00 billion by 2035, at a CAGR of 4.15%. The table below outlines the year-over-year market values (in USD billion), calculated using the compound growth formula.

Year Market Value (USD Billion)
2025 2.00
2026 2.08
2027 2.17
2028 2.26
2029 2.35
2030 2.45
2031 2.55
2032 2.66
2033 2.77
2034 2.88
2035 3.00

Market Share

The market is segmented by product type, route of administration, and application:

  • By Product Type (2025 estimates): Gentamicin holds the largest share at approximately 34%, due to its broad efficacy against Gram-negative bacteria. Tobramycin follows with around 25%, particularly for respiratory applications like cystic fibrosis. Other types include Amikacin (~15%), Neomycin (~10%), and others (e.g., Streptomycin, Kanamycin) at 16%.
  • By Route of Administration: Injectable forms dominate with ~27% share, favored for severe infections, while oral routes are growing due to improved bioavailability.
  • By Application: Respiratory diseases lead with ~37% share, driven by infections like pneumonia and tuberculosis. Skin infections and urinary tract infections (UTIs) account for significant portions, with veterinary applications also notable.

Trends

  • Formulation Innovations: Development of liposomal and nebulized delivery systems to reduce nephrotoxicity and ototoxicity while enhancing efficacy.
  • Antimicrobial Resistance (AMR) Focus: Increased use in combination therapies to combat resistant strains, with research into nanoparticle-conjugated aminoglycosides.
  • Veterinary Applications: Rising demand in animal health for treating infections in livestock and pets.
  • Digital Health Integration: Adoption of AI for dosing optimization and monitoring to minimize side effects.

Growth Drivers

  • Increasing Bacterial Infections: High prevalence of Gram-negative infections, tuberculosis, and AMR globally, necessitating effective antibiotics.
  • Advancements in Drug Delivery: New formulations improving safety and patient compliance, expanding use in chronic conditions like cystic fibrosis.
  • Rising Awareness and Diagnosis: Enhanced screening for infections, particularly in vulnerable populations, boosting prescription rates.
  • Veterinary Demand: Growth in animal healthcare due to food safety concerns and pet humanization.

Strategic Analysis

The aminoglycosides market is moderately competitive, with established players focusing on R&D to mitigate side effects and regulatory challenges. Strategies include mergers for portfolio expansion (e.g., acquisitions in delivery tech) and partnerships for combination therapies. Challenges like toxicity risks and generic competition require emphasis on innovative formulations and compliance with stringent FDA/EMA standards. Opportunities lie in AMR-targeted drugs and veterinary segments, favoring companies investing in sustainable production and emerging markets.

Key Players

Major players in the aminoglycosides market include:

  • Pfizer Inc.
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Aurobindo Pharma Limited
  • Fresenius Kabi
  • Viatris Inc.
  • Others: Zoetis Inc., Insmed Incorporated, Vega Pharma

Recent developments include Pfizer's acquisition of Nektar Therapeutics in 2023 for advanced delivery systems and ongoing trials for next-gen formulations.

Generated image

Table of Content

  1. Market Overview
    1. Research Methodology
    2. Definitions and Scope
  2. Market - Executive Summary
    1. Market Opportunity
    2. Key Trends by Product Segments
    3. Key Trends by Geography
  3. Aminoglycosides Market Landscape
    1. Comparative analysis
      1. Product Benchmarking - Top 10 companies
      2. Top 5 Financials Analysis
      3. Market Value split by Top 10 companies
      4. Pricing Analysis
  4. Market Forces
    1. Market Drivers
      1. Increasing animal illness outbreaks
      2. Rising Cases of Chronic Diseases
    2. Market Constraints
      1. Adverse and Hazardous Effects of Aminoglycosides
      2. Other Constraints
    3. Market Challenges
    4. Porter’s Five Forces
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Degree of Competition
  5. Aminoglycosides Market - Strategic Analysis
    1. Value Chain
    2. Opportunity
    3. Patent Analysis
  6. Global Aminoglycosides Market Outlook
    1. Global Aminoglycosides Market Outlook, by Product, 2019-2029
      1. Neomycin
      2. Tobramycin
      3. Gentamicin
      4. Amikacin
      5. Paromomycin
      6. Streptomycin
      7. Kanamycin
      8. Other Aminoglycosides
    2. Global Aminoglycosides Market Outlook, by Administration, 2019-2029
      1. Feed
      2. Injectable
      3. Intra-mammary
      4. Topical
      5. Oral
    3. Global Aminoglycosides Market Outlook, by Application, 2019-2029
      1. Veterinary
      2. Skin Infection
      3. Respiratory Diseases
      4. UTI & Pelvic Diseases
      5. Other Diseases
  7. Asia Pacific Aminoglycosides Market Outlook
    1. Key Snapshot
    2. Asia Pacific Aminoglycosides Market Outlook, by Product, 2019-2029
      1. Neomycin
      2. Tobramycin
      3. Gentamicin
      4. Amikacin
      5. Paromomycin
      6. Streptomycin
      7. Kanamycin
      8. Other Aminoglycosides
    3. Asia Pacific Aminoglycosides Market Outlook, by Administration, 2019-2029
      1. Feed
      2. Injectable
      3. Intra-mammary
      4. Topical
      5. Oral
    4. Asia Pacific Aminoglycosides Market Outlook, by Administration, 2019-2029
      1. Veterinary
      2. Skin Infection
      3. Respiratory Diseases
      4. UTI & Pelvic Diseases
      5. Other Diseases
    5. Asia Pacific Aminoglycosides Market Outlook, by Country, 2019-2029
      1. China Aminoglycosides Market Outlook, 2019-2029
      2. India Aminoglycosides Market Outlook, 2019-2029
      3. Japan Aminoglycosides Market Outlook, 2019-2029
      4. South Korea Aminoglycosides Market Outlook, 2019-2029
      5. Australia Aminoglycosides Market Outlook, 2019-2029
      6. Rest of Asia Pacific Aminoglycosides Market Outlook, 2019-2029
  8. North America Aminoglycosides Market Outlook
    1. Key Snapshot
    2. North America Aminoglycosides Market Outlook, by Product, 2019-2029
      1. Neomycin
      2. Tobramycin
      3. Gentamicin
      4. Amikacin
      5. Paromomycin
      6. Streptomycin
      7. Kanamycin
      8. Other Aminoglycosides
    3. North America Aminoglycosides Market Outlook, by Administration, 2019-2029
      1. Feed
      2. Injectable
      3. Intra-mammary
      4. Topical
      5. Oral
    4. North America Aminoglycosides Market Outlook, by Administration, 2019-2029
      1. Veterinary
      2. Skin Infection
      3. Respiratory Diseases
      4. UTI & Pelvic Diseases
      5. Other Diseases
    5. North America Aminoglycosides Market Outlook, by Country, 2019-2029
      1. United States Aminoglycosides Market Outlook, 2019-2029
      2. Canada Aminoglycosides Market Outlook, 2019-2029
      3. Mexico Aminoglycosides Market Outlook, 2019-2029
  9. Europe Aminoglycosides Market Outlook
    1. Key Snapshot
    2. Europe Aminoglycosides Market Outlook, by Product, 2019-2029
      1. Neomycin
      2. Tobramycin
      3. Gentamicin
      4. Amikacin
      5. Paromomycin
      6. Streptomycin
      7. Kanamycin
      8. Other Aminoglycosides
    3. Europe Aminoglycosides Market Outlook, by Administration, 2019-2029
      1. Feed
      2. Injectable
      3. Intra-mammary
      4. Topical
      5. Oral
    4. Europe Aminoglycosides Market Outlook, by Administration, 2019-2029
      1. Veterinary
      2. Skin Infection
      3. Respiratory Diseases
      4. UTI & Pelvic Diseases
      5. Other Diseases
    5. Europe Aminoglycosides Market Outlook, by Country, 2019-2029
      1. United Kingdom Aminoglycosides Market Outlook, 2019-2029
      2. Germany Aminoglycosides Market Outlook, 2019-2029
      3. France Aminoglycosides Market Outlook, 2019-2029
      4. Italy Aminoglycosides Market Outlook, 2019-2029
      5. Russia Aminoglycosides Market Outlook, 2019-2029
      6. Rest of Europe Aminoglycosides Market Outlook, 2019-2029
  10. Latin America Aminoglycosides Market Outlook
    1. Key Snapshot
    2. Latin America Aminoglycosides Market Outlook, by Product, 2019-2029
      1. Neomycin
      2. Tobramycin
      3. Gentamicin
      4. Amikacin
      5. Paromomycin
      6. Streptomycin
      7. Kanamycin
      8. Other Aminoglycosides
    3. Latin America Aminoglycosides Market Outlook, by Administration, 2019-2029
      1. Feed
      2. Injectable
      3. Intra-mammary
      4. Topical
      5. Oral
    4. Latin America Aminoglycosides Market Outlook, by Administration, 2019-2029
      1. Veterinary
      2. Skin Infection
      3. Respiratory Diseases
      4. UTI & Pelvic Diseases
      5. Other Diseases
    5. Latin America Aminoglycosides Market Outlook, by Country, 2019-2029
      1. Brazil Aminoglycosides Market Outlook, 2019-2029
      2. Argentina Aminoglycosides Market Outlook, 2019-2029
      3. Rest of Latin America Aminoglycosides Market Outlook, 2019-2029
  11. Middle East and Africa Aminoglycosides Market Outlook
    1. Key Snapshot
    2. Middle East and Africa Aminoglycosides Market Outlook, by Product, 2019-2029
      1. Neomycin
      2. Tobramycin
      3. Gentamicin
      4. Amikacin
      5. Paromomycin
      6. Streptomycin
      7. Kanamycin
      8. Other Aminoglycosides
    3. Middle East and Africa Aminoglycosides Market Outlook, by Administration, 2019-2029
      1. Feed
      2. Injectable
      3. Intra-mammary
      4. Topical
      5. Oral
    4. Middle East and Africa Aminoglycosides Market Outlook, by Administration, 2019-2029
      1. Veterinary
      2. Skin Infection
      3. Respiratory Diseases
      4. UTI & Pelvic Diseases
      5. Other Diseases
    5. Middle East and Africa Aminoglycosides Market Outlook, by Country, 2019-2029
      1. Saudi Arabia Aminoglycosides Market Outlook, 2019-2029
      2. UAE Aminoglycosides Market Outlook, 2019-2029
      3. South Africa Aminoglycosides Market Outlook, 2019-2029
      4. Rest of Middle East and Africa Aminoglycosides Market Outlook, 2019-2029
  12. Aminoglycosides Market -Entropy
    1. New Product Launches
    2. M&A, Collaborations, JVs, and Partnerships
  13. Aminoglycosides Market Company Analysis
    1. Market Share Analysis, Financial Analysis, Product Synopsis, Recent News, and Developments
    2. Cipla Limited
    3. Zoetis Inc.
    4. AbbVie Inc. (Allergan PLC)
    5. Johnson & Johnson
    6. Pfizer Inc.
    7. Vega Pharma Ltd
    8. Xian Wison Biological Technology Co. Ltd
    9. Yi Chang Veterinary Medicine Factory
    10. Insmed Incorporated
    11. Teva Pharmaceutical Industries Ltd

Top Major Players List :- Aminoglycosides Market

  • Cipla Limited
  • Zoetis Inc
  • AbbVie Inc (Allergan PLC)
  • Johnson & Johnson
  • Pfizer Inc
  • Vega Pharma Ltd
  • Xian Wison Biological Technology Co Ltd
  • Yi Chang Veterinary Medicine Factory
  • Insmed Incorporated
  • Teva Pharmaceutical Industries Ltd

SELECT LICENCE TYPE

  • Single User Licence     $2950
  • Multi User Licence     $4950
  • Enterprice User Licence     $6950


Related Reports